24/7 Market News Snapshot 14 August, 2025 – BIOMERICA INC (NASDAQ:BMRA)

August 14, 2025

DENVER, Colo., 14 August, 2025 (www.247marketnews.com) – (NASDAQ:BMRA) are discussed in this article.
Biomerica Inc. has been generating substantial investor interest, evidenced by a notable 33.60% increase in its stock price, now standing at $4.048 in pre-market trading. The surge follows the recent announcement of the approval of their Fortel® Ulcer Test for home use, contributing to heightened market activity with around 1.67 million shares traded. This upward trajectory not only reflects strong momentum but also indicates potential for further gains as investors respond to the company’s strategic advancements.

The Fortel® Ulcer Test is a rapid diagnostic tool capable of detecting Helicobacter pylori (H. pylori) in just ten minutes, a major breakthrough in home diagnostics. H. pylori is linked to a significant incidence of peptic ulcers and gastric cancer, responsible for approximately 80% of cases and classified as a Class 1 carcinogen by the World Health Organization. With a large segment of the population exposed to this risk, early detection becomes crucial in preventing serious health complications, including chronic digestive disorders.

Zack Irani, CEO of Biomerica, emphasized the test’s role in enhancing patient access to vital diagnostics, stating, “With the approval of the Fortel® Ulcer Test for home use, we are revolutionizing access to critical diagnostic tools.” This initiative not only supports timely medical intervention but also aligns with the company’s commitment to improving global health outcomes.

Biomerica’s collaboration with local distributors and healthcare providers aims to ensure broad availability of the Fortel® Ulcer Test through pharmacies and online platforms, thus facilitating greater access to essential health resources. As the company continues to innovate in gastrointestinal health management, it solidifies its mission to empower individuals with the tools necessary for early disease detection while aiming to reduce overall healthcare costs. The launch of the Fortel® Ulcer Test could serve as a significant milestone in advancing patient-centric care and overall health management.

Related news for (BMRA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.